Higher Tetanus Toxoid Immunity 2 Years After PsA-TT Introduction in Mali | Zendy

Nicole E. Basta | Zendy; Ray Borrow | Zendy; Abdoulaye Berthe | Zendy; Uma Onwuchekwa | Zendy; Awa Traoré Eps Dembélé | Zendy; Rachael Almond | Zendy; Sarah Frankland | Zendy; Sima Patel | Zendy; D.J. Wood | Zendy; Maria Isabel do Nascimento | Zendy; Olivier Manigart | Zendy; Caroline Trotter | Zendy; Brian Greenwood | Zendy; Samba O. Sow | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Higher Tetanus Toxoid Immunity 2 Years After PsA-TT Introduction in Mali

Author(s) -

Nicole E. Basta,

Ray Borrow,

Abdoulaye Berthe,

Uma Onwuchekwa,

Awa Traoré Eps Dembélé,

Rachael Almond,

Sarah Frankland,

Sima Patel,

D.J. Wood,

Maria Isabel do Nascimento,

Olivier Manigart,

Caroline Trotter,

Brian Greenwood,

Samba O. Sow

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ513

Subject(s) - toxoid , tetanus , medicine , immunity , vaccination , immunology , herd immunity , population , conjugate vaccine , cellular immunity , immunization , antigen , immune system , environmental health

In 2010, mass vaccination with a then-new meningococcal A polysaccharide-tetanus toxoid protein conjugate vaccine (PsA-TT, or MenAfriVac) was undertaken in 1- to 29-year-olds in Bamako, Mali. Whether vaccination with PsA-TT effectively boosts tetanus immunity in a population with heterogeneous baseline tetanus immunity is not known. We assessed the impact of PsA-TT on tetanus toxoid (TT) immunity by quantifying age- and sex-specific immunity prior to and 2 years after introduction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research